deca durabolin 100 mg ml injection - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

deca durabolin 100mg/ml, solution for injection (a 100 mg/ml solution for injection

organon laboratories limited - nandrolone decanoate - solution for injection - 100 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

deca durabolin 100mg/ml, solution for injection (a

organon laboratories limited - nandrolone decanoate - solution for injection - 100 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

deca-durabolin orgaject 50mg/1ml injection ampoule

aspen pharmacare australia pty ltd - nandrolone decanoate, quantity: 50 mg/ml - injection, solution - excipient ingredients: arachis oil; benzyl alcohol - indications as at 16 april 1997. acute renal failure, chronic renal insufficiency and anaemia of chronic renal failure. for the palliative treatment of inoperable mammary carcinoma. osteoporosis (where oestrogen therapy is contraindicated). aplastic anaemia. patients on long-term treatment with corticosteriods.

New Zealand - English - Medsafe (Medicines Safety Authority)

deca-durabolin orgaject

pharmacy retailing (nz) ltd t/a healthcare logistics - nandrolone decanoate 25 mg/ml - solution for injection - 25 mg/ml - active: nandrolone decanoate 25 mg/ml excipient: arachis oil benzyl alcohol - deca-durabolin can be used for the treatment of osteoporosis; for the palliative treatment of selected cases of disseminated mammary carcinoma in women and as an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance.

New Zealand - English - Medsafe (Medicines Safety Authority)

deca-durabolin orgaject

pharmacy retailing (nz) ltd t/a healthcare logistics - nandrolone decanoate 50 mg/ml - solution for injection - 50 mg/ml - active: nandrolone decanoate 50 mg/ml excipient: arachis oil benzyl alcohol - deca-durabolin can be used for the treatment of osteoporosis; for the palliative treatment of selected cases of disseminated mammary carcinoma in women and as an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance.